Docket No.: 0259-0417P

Amendments to the Claims

1. (Previously Presented) A phosphatidyl-L-serine sodium salt having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

2. (Previously Presented) A phosphatidyl-L-serine sodium salt having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from egg, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

3. (Previously Presented) A phosphatidyl-L-serine sodium salt having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

4. (Previously Presented) A phosphatidyl-L-serine sodium salt having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$ with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

5. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a phosphatidyl-L-serine sodium salt of formula (I)

$$R - O - PO(OH) - O - R_1 \qquad (I)$$

wherein R is diacylglycerol and R₁ is a hydrogen,

Docket No.: 0259-0417P

made by the process of reacting a phosphatide of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction to obtain said phosphatide according to formula (I), and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

6. (Previously Presented) A cosmetic composition comprising a pharmaceutically acceptable carrier and a phosphatidyl-L-serine sodium salt of formula (I)

$$R - O - PO(OH) - O - R_1$$
 (I

wherein R is diacylglycerol and R₁ is a hydrogen,

made by the process of reacting a phosphatide of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction to obtain said phosphatide according to formula (I), and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

7. (Previously Presented) A food and dietary supplement comprising a carrier and a phosphatidyl-L-serine sodium salt of formula (I)

Application No. 10/663,198 Amendment dated October 22, 2008 After Final Office Action of June 23, 2008 Docket No.: 0259-0417P

$$R - O - PO(OH) - O - R_1 \qquad (I)$$

wherein R is diacylglycerol and R₁ is a hydrogen,

made by the process of reacting a phosphatide of formula (II):

$$R - O - PO(OH) - O - R_2$$
 (II)

wherein R is diacylglycerol and R_2 is $CH_2 - CH_2 - NH_2$ or $CH_2 - CH_2 - N(CH_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a Streptomyces hachijoense strain to catalyze the reaction to obtain said phosphatide according to formula (I), and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is over 95% pure.

- 8. (Previously Presented) The food and dietary supplement according to claim 7, wherein the Streptomyces hachijoense strain is ATCC 19769.
- 9. (Previously Presented) A pharmaceutical composition capable of being administered orally comprising a pharmaceutically acceptable carrier and the phosphatidyl-L-serine sodium salt according to claim 1, 2, 3 or 4.
- 10. (Previously Presented) A cosmetic composition for topical application to the skin comprising a pharmaceutically acceptable carrier and the phosphatidyl-L-serine sodium salt according to claim 1, 2, 3 or 4.
- 11. (Previously Presented) A food and dietary supplement capable of being administered orally comprising a carrier and the phosphatidyl-L-serine sodium salt according to claim 1, 2, 3 or 4.

12-14. (Canceled)

15. (Previously Presented) The pharmaceutical composition according to claim 5 in the form of

a capsule, tablet or granule.

16. (Previously Presented) The cosmetic composition according to claim 6 in the form of a

cream or a gel.

17. (Original) A food and dietary supplement according to claim 7 in the form of a capsule,

tablet or granule.

18. (Original) A food and dietary supplement according to claim 11 in the form of a capsule,

tablet or granule.

19. (Original) The food and dietary supplement according to claim 8, wherein the phosphatide

of formula (II) is selected from the group consisting of purified soybean lecithin and crude

soybean lecithin.

20. (Canceled)

21. (Currently Amended) The phosphatidyl-L-serine according to claim 1 or 2, wherein the

formula II phosphatide reactant is phosphatidylcholine, and wherein said phosphatidylcholine

6

reactant is completely converted to a phosphatidyl-L-serine sodium salt.

22. (Canceled)

LRS/MHE/cjd

Docket No.: 0259-0417P